Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DERM NASDAQ:ENTA NASDAQ:NXTC NASDAQ:ODT NASDAQ:RCKT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDERMJourney Medical$7.11-3.3%$7.28$3.54▼$8.90$193.38M0.8148,143 shs135,482 shsENTAEnanta Pharmaceuticals$8.28-4.4%$7.86$4.09▼$13.37$185.13M0.84152,052 shs223,754 shsNXTCNextCure$5.30-2.7%$5.12$2.69▼$19.20$14.56M1.2716,626 shs2,456 shsODTOdonate Therapeutics$1.27$0.85▼$7.10N/AN/AN/A87,682 shsRCKTRocket Pharmaceuticals$3.16-3.7%$3.16$2.19▼$22.01$353.92M0.625.59 million shs1.83 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDERMJourney Medical0.00%+1.43%-2.07%+4.87%+48.43%ENTAEnanta Pharmaceuticals0.00%-6.44%+6.98%+10.40%-31.23%NXTCNextCure0.00%+7.73%+2.82%-35.21%-67.32%ODTOdonate Therapeutics0.00%0.00%0.00%0.00%0.00%RCKTRocket Pharmaceuticals0.00%-3.66%+4.29%+7.85%-83.39%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDERMJourney Medical$7.11-3.3%$7.28$3.54▼$8.90$193.38M0.8148,143 shs135,482 shsENTAEnanta Pharmaceuticals$8.28-4.4%$7.86$4.09▼$13.37$185.13M0.84152,052 shs223,754 shsNXTCNextCure$5.30-2.7%$5.12$2.69▼$19.20$14.56M1.2716,626 shs2,456 shsODTOdonate Therapeutics$1.27$0.85▼$7.10N/AN/AN/A87,682 shsRCKTRocket Pharmaceuticals$3.16-3.7%$3.16$2.19▼$22.01$353.92M0.625.59 million shs1.83 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDERMJourney Medical0.00%+1.43%-2.07%+4.87%+48.43%ENTAEnanta Pharmaceuticals0.00%-6.44%+6.98%+10.40%-31.23%NXTCNextCure0.00%+7.73%+2.82%-35.21%-67.32%ODTOdonate Therapeutics0.00%0.00%0.00%0.00%0.00%RCKTRocket Pharmaceuticals0.00%-3.66%+4.29%+7.85%-83.39%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDERMJourney Medical 2.50Moderate Buy$12.1771.12% UpsideENTAEnanta Pharmaceuticals 3.00Buy$22.25168.72% UpsideNXTCNextCure 2.67Moderate Buy$25.50381.59% UpsideODTOdonate Therapeutics 0.00N/AN/AN/ARCKTRocket Pharmaceuticals 2.41Hold$16.73429.54% UpsideCurrent Analyst Ratings BreakdownLatest NXTC, DERM, ODT, RCKT, and ENTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/2/2025ENTAEnanta PharmaceuticalsWestpark CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$24.008/25/2025DERMJourney MedicalHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$13.008/20/2025RCKTRocket PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$4.00 ➝ $10.008/20/2025RCKTRocket PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.008/15/2025DERMJourney MedicalZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell8/13/2025DERMJourney MedicalLake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $13.008/12/2025ENTAEnanta PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$24.00 ➝ $25.008/11/2025RCKTRocket PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $11.008/8/2025RCKTRocket PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$10.00 ➝ $8.007/28/2025ENTAEnanta PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$20.007/25/2025RCKTRocket PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$11.00 ➝ $10.00(Data available from 9/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDERMJourney Medical$56.40M3.32N/AN/A$0.91 per share7.81ENTAEnanta Pharmaceuticals$67.64M2.62N/AN/A$6.08 per share1.36NXTCNextCureN/AN/AN/AN/A$28.06 per shareN/AODTOdonate TherapeuticsN/AN/AN/AN/AN/AN/ARCKTRocket PharmaceuticalsN/AN/AN/AN/A$5.08 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDERMJourney Medical-$14.67M-$0.38N/AN/AN/A-15.49%-48.69%-11.26%11/11/2025 (Estimated)ENTAEnanta Pharmaceuticals-$116.04M-$4.32N/AN/AN/A-141.98%-89.02%-27.28%11/24/2025 (Estimated)NXTCNextCure-$55.65M-$25.82N/AN/AN/AN/A-106.62%-85.20%11/6/2025 (Estimated)ODTOdonate Therapeutics-$126.35MN/A0.00N/AN/AN/AN/AN/AN/ARCKTRocket Pharmaceuticals-$258.75M-$2.51N/AN/AN/AN/A-65.11%-55.99%11/6/2025 (Estimated)Latest NXTC, DERM, ODT, RCKT, and ENTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025DERMJourney Medical-$0.07-$0.16-$0.09-$0.16$14.93 million$15.01 million8/11/2025Q3 2025ENTAEnanta Pharmaceuticals-$1.25-$0.85+$0.40-$0.85$16.21 million$18.31 million8/7/2025Q2 2025NXTCNextCure-$4.62-$11.29-$6.67-$11.29N/AN/A8/7/2025Q2 2025RCKTRocket Pharmaceuticals-$0.57-$0.59-$0.02-$0.62$4.36 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDERMJourney MedicalN/AN/AN/AN/AN/AENTAEnanta PharmaceuticalsN/AN/AN/AN/AN/ANXTCNextCureN/AN/AN/AN/AN/AODTOdonate TherapeuticsN/AN/AN/AN/AN/ARCKTRocket PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDERMJourney Medical1.111.270.95ENTAEnanta PharmaceuticalsN/A5.005.00NXTCNextCureN/A3.713.71ODTOdonate TherapeuticsN/AN/AN/ARCKTRocket Pharmaceuticals0.056.396.39Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDERMJourney Medical7.25%ENTAEnanta Pharmaceuticals94.99%NXTCNextCure42.65%ODTOdonate TherapeuticsN/ARCKTRocket Pharmaceuticals98.39%Insider OwnershipCompanyInsider OwnershipDERMJourney Medical15.03%ENTAEnanta Pharmaceuticals13.89%NXTCNextCure17.90%ODTOdonate Therapeutics48.90%RCKTRocket Pharmaceuticals24.76%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDERMJourney Medical9026.31 million22.36 millionN/AENTAEnanta Pharmaceuticals16021.38 million18.41 millionOptionableNXTCNextCure902.68 million2.20 millionOptionableODTOdonate Therapeutics14528.53 million14.58 millionNot OptionableRCKTRocket Pharmaceuticals240107.90 million81.19 millionOptionableNXTC, DERM, ODT, RCKT, and ENTA HeadlinesRecent News About These CompaniesRocket Pharmaceuticals, Inc. (RCKT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 9, 2025 | seekingalpha.comRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Consensus Recommendation of "Hold" from BrokeragesSeptember 7, 2025 | marketbeat.comRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Given Consensus Recommendation of "Hold" by BrokeragesSeptember 5, 2025 | americanbankingnews.comMPM Bioimpact LLC Buys 597,706 Shares of Rocket Pharmaceuticals, Inc. $RCKTSeptember 4, 2025 | marketbeat.comFrazier Life Sciences Management L.P. Sells 400,000 Shares of Rocket Pharmaceuticals, Inc. $RCKTSeptember 4, 2025 | marketbeat.comRocket Pharmaceuticals, Inc. $RCKT Shares Bought by Baker BROS. Advisors LPSeptember 4, 2025 | marketbeat.comRussell Investments Group Ltd. Sells 767,219 Shares of Rocket Pharmaceuticals, Inc. $RCKTSeptember 4, 2025 | marketbeat.com629,749 Shares in Rocket Pharmaceuticals, Inc. $RCKT Acquired by Nantahala Capital Management LLCSeptember 3, 2025 | marketbeat.comNuveen LLC Makes New Investment in Rocket Pharmaceuticals, Inc. $RCKTSeptember 2, 2025 | marketbeat.comJump Financial LLC Invests $1.69 Million in Rocket Pharmaceuticals, Inc. $RCKTAugust 30, 2025 | marketbeat.comSynovus Financial Corp Has $1.86 Million Stock Holdings in Rocket Pharmaceuticals, Inc. $RCKTAugust 29, 2025 | marketbeat.comElisabeth Bjork Buys 10,000 Shares of Rocket Pharmaceuticals (NASDAQ:RCKT) StockAugust 28, 2025 | insidertrades.comAlphaQuest LLC Increases Holdings in Rocket Pharmaceuticals, Inc. $RCKTAugust 28, 2025 | marketbeat.comRocket Pharmaceuticals CFO Aaron Ondrey resigns to pursue other opportunitiesAugust 25, 2025 | msn.comWellington Management Group LLP Reduces Stock Holdings in Rocket Pharmaceuticals, Inc. $RCKTAugust 25, 2025 | marketbeat.comWilliam Blair Issues Negative Forecast for RCKT EarningsAugust 24, 2025 | marketbeat.comEMA says Rocket Pharmaceuticals withdraws MA application for FanskyaAugust 22, 2025 | msn.comRocket Pharmaceuticals: Good News As Clinical Hold Lifted - But Challenges RemainAugust 22, 2025 | seekingalpha.comRocket Pharmaceuticals (RCKT) Receives a Sell from Goldman SachsAugust 22, 2025 | theglobeandmail.comRCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease StudyAugust 21, 2025 | zacks.comRocket Pharmaceuticals announces clinical hold lifted on RP-A501 trialAugust 20, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNXTC, DERM, ODT, RCKT, and ENTA Company DescriptionsJourney Medical NASDAQ:DERM$7.11 -0.24 (-3.27%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$7.14 +0.03 (+0.42%) As of 09/12/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.Enanta Pharmaceuticals NASDAQ:ENTA$8.28 -0.38 (-4.39%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$8.28 0.00 (-0.06%) As of 09/12/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.NextCure NASDAQ:NXTC$5.30 -0.15 (-2.67%) Closing price 09/12/2025 03:50 PM EasternExtended Trading$5.38 +0.08 (+1.51%) As of 09/12/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.Odonate Therapeutics NASDAQ:ODTOdonate Therapeutics is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Our initial focus is on the development of tesetaxel, a novel chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Tesetaxel has several potential therapeutic advantages over currently available taxanes, including: oral administration with a low pill burden and a patient-friendly dosing regimen; a formulation that does not contain solubilizing agents that are known to cause hypersensitivity (allergic) reactions; and improved activity against chemotherapy-resistant tumors. Tesetaxel has been generally well tolerated in clinical studies and has demonstrated robust single-agent antitumor activity in two Phase 2 studies in patients with locally advanced or metastatic breast cancer (''MBC'').Rocket Pharmaceuticals NASDAQ:RCKT$3.16 -0.12 (-3.66%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$3.17 +0.01 (+0.32%) As of 09/12/2025 06:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
